LIAISON PLEX® Bloodstream Infection Portfolio
Empower clinicians to rapidly optimize treatment and patient management
Dhiman N, Emery CL, Chow S, Ho D, Granato P, Bernier B, Farhang J. 2026. Performance of the LIAISON PLEX gram-negative blood culture assay for identifying bacterial pathogens and resistance genes in blood cultures. J Clin Microbiol64:e00018-26.
https://doi.org/10.1128/jcm.00018-26I
Time is critical
Bloodstream infections demand faster answers
Clinical guidelines emphasize rapid diagnostics from positive blood cultures to speed up pathogen identification and antimicrobial resistance detection, helping clinicians optimize therapy sooner and improve outcomes through active antimicrobial stewardship.
Wolk DM, Parrott JS, Babady NE, Mochon AB, Tom R, Diel C, Dien Bard J, Harrington A, Hata DJ, Roberts AL, Boyce L, Johnson JK. 0. The American Society for Microbiology’s evidence-based laboratory medicine practice guidelines for the diagnosis of bloodstream infections using rapid tests: a systematic review and meta-analysis. Clin Microbiol Rev 0:e00137-24.
https://doi.org/10.1128/cmr.00137-24
Value of rapid molecular diagnostics
The LIAISON PLEX® Bloodstream Infection Portfolio
The LIAISON PLEX® Bloodstream Infection Solution combines three targeted molecular assays.
- 60 targets: 48 bacteria/yeast pathogens and 12 resistance genes.
- Split Panel Design: Streamline workflow.
- Flexibility to meet patient-specific needs.
- Comprehensive pathogen and resistance gene detection.
- Optimal chemistry: Direct detection* or PCR.
*For BCP, BCN
Designed for clinical impact
Diagnostic accuracy
Gram stain guided
Limit low probability pathogens
Clarity and confidence
Control costs
Run the panels you need
Reduce unnecessary testing
Avoid the added cost
Diagnostic workflow
Positive blood culture
A positive blood culture indicates the presence of a microorganism requiring further investigation.
Sample classification
Gram stain results help classify the microorganism and guide the diagnostic pathway.
Assay selection
The appropriate Gram-positive, Gram-negative or Yeast assay is selected based on the sample profile.
Rapid clinical insights
Pathogen identification and resistance gene detection provide clinically relevant information to support treatment optimization.
Bloodstream Infection Solution assays menu
LIAISON PLEX® Gram-Positive Blood Culture Assay
17
Total targets
Overall sensitivity*: 98.5%1
Overall specificity*: 99.7%1
* across panel targets
1 doi: 10.1128/JCM.00235-26
Gram-Positive Bacteria | Resistance Genes | |
|---|---|---|
Bacillus spp. | Staphylococcus lugdunensis | mecA/mecC |
Enterococcus faecalis | Streptococcus spp. | vanA |
Enterococcus faecium | Streptococcus agalactiae | vanB |
Listeria spp. | Streptococcus anginosus group | |
Staphylococcus spp. | Streptococcus pneumoniae | |
Staphyloccocus aureus | Streptococcus pyogenes | |
Staphylococcus epidermidis |
Ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
LIAISON PLEX® Gram-Positive Blood Culture Assay |
12 |
IVD |
20-005-305 |
LIAISON PLEX® Gram-Negative Blood Culture Assay
27
Total targets
Overall sensitivity*: 98.6%1
Overall specificity*: 99.9%1
* across panel targets
1 doi: 10.1128/JCM.00018-26
Gram-Negative Bacteria | Resistance Genes | |
|---|---|---|
Acinetobacter baumannii | Klebsiella variicola | CTX-M (blaCTX-M) |
Acinetobacter spp. | Morganella morganii | IMP (blaIMP) |
Citrobacter spp. | Neisseria meningitidis | KPC (blaKPC) |
Enterobacter spp. | Proteus spp. | NDM (blaNDM) |
Enterobacteriaceae/Morganellaceae | Pseudomonas aeruginosa | OXA (blaOXA) |
Escherichia coli | Pseudomonas spp. | SME (blaSME) |
Haemophilus influenzae | Salmonella spp. | VIM (blaVIM) |
Klebsiella oxytoca | Serratia marcescens | MCR |
Klebsiella pneumoniae | Stenotrophomonas maltophilia |
Ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
LIAISON PLEX® Gram-Negative Blood Culture Assay |
12 |
IVD |
20-005-303 |
LIAISON PLEX® Yeast Blood Culture Assay
16
Total targets
Overall sensitivity*: 98.5%1
Overall specificity*: 99.7%1
* across panel targets
1 doi: 10.1128/JCM.00362-25
Yeast | |
|---|---|
Candida albicans | Candida kefyr |
Candida auris | Candida krusei |
Candida dubliniensis | Candida lipolytica |
Candida famata | Candida lusitaniae |
Candida glabrata | Candida parapsilosis |
Candida guilliermondii | Candida tropicalis |
Candida haemulonii/duobushaemulonii | Cryptococcus neoformans/gattii |
Ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
LIAISON PLEX® Yeast Blood Culture Assay |
12 |
IVD |
20-005-306 |
To be used on the LIAISON PLEX® System
The LIAISON PLEX® System is a next-generation, multiplex, sample-to-answer molecular diagnostic platform. Designed to support both PCR and non-amplified assays, offering the most optimal testing approach for each patient, ensuring precise and personalized diagnostics.
LIAISON PLEX®
Flexibility like never before with an easy-to-use, automated system for customizable syndromic testing.
Related products
LIAISON PLEX®
LIAISON PLEX® Gastrointestinal Flex Assay
A customizable gastrointestinal solution designed to return testing decisions back to clinicians and laboratories.
LIAISON PLEX®
LIAISON PLEX® Respiratory Flex Assay
Sample-to-customizable answer for your respiratory testing.
TECHNOLOGY
LIAISON PLEX® Flex™ Testing
Customize panels to patient need, report only what’s necessary, and expand results without retesting.
Appropriate testing and treatment impacts patient outcomes. At Diasorin, we are committed to improving diagnostics to support clinical decisions.
Working together
Sepsis Alliance
Diasorin is a proud sponsor of Sepsis Alliance, a leading nonprofit patient advocacy organization.
